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several law phase IL1 trjds, hirudin. iB (wing cqwed with. 
lpzqmri~ for ai! &r+ fn@caHo+ la thi t’$st p&es BP these tria!s : 
she rate of hemwrkgic evei&; in&ding irttracra~W tremor- 
dmge, was higher than expkcted in both the bin&a and beparin 
srm, which demoristrated that a’ safety ceiling bad been w+&ed. 
The refmnulated ThfonWlysis in Mywardial Lntspctioo (TIFVII) 
9 and SeMnd Global Use of &rate&s to Open Occlde.! Cera- 
naq tb-m-ies (GUSTO Ii) triafs an? asing lower doses of bitudh 
aad hep&a, wbtcb sbcndd aflow tkslitig of tietlwr the initial 
,favorihle~ malts &served in @ot t&&7 ,*I ,Sanslate into 
improved c@b!al o@cOlne, with an raeceptabte s+Pty prow$ far 
pzriieats with au&e myx+cadal mfaFetion or nnstzble an,,$na 0T 
those uadergoiug angiaplasty. 
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rep&&ion of the infarct-xlaited &tery is not achkzed in IS% 
to 20% of patients (18,19); 2) an additional 15% to.20% of 
patiehts achieve only incomplete perfusion (i.e., Tkombolysis 
in Myocardial, infarction [nMlj grade 2 flow) (18-21;); 3) after 
successful reperfusioon! ~occtusion of the infarct-related artery 
or its clinicat correlate, reinfarction,: dr both, occurs ira =% to 
10% of patients at hospital discharge (19,21) and in up tr, 30% 
of patients at 3 months (22). ln Unstable angina, progression to 
,myecardial. infaktibn: still 0.Lxurs in ,S% to-, 7% of patients. 
(1?,23), and in k&p&y; abrupt closure~r m+&lid inf&ci 
tion complicates the procedure in 5% to 10% ‘6f patients, with 
an additional Sk to 10% of patients requiriq urgent repeat 
reva&$ar$ation (12,24&26). In ali nf these syndromes, these 
thro+otic events are askated with ineva+d mo@lity 
(12,21+27-32) a&thus ire important &g+xftir rnory e+ctivei~ 
amitttrombo’tic fk*py. 
m clinikal ~ti@atio& in the current trektinent of atite 
cmonary syndromes-tiay be expjajned by, me ‘@nitations of 
aspirin’and:heparin 5s ph&+txlog!c acents. Although aspirin 
id~v3sibl~ inKbit&piatelet cjdoo&enase, the +werfuhtim- 
‘ulato& e&xt ot $kr!bitl (or otkr stimuli, suc$ as serotonia 
qr ‘hi& c@xentration’; of ~oQag&) c*1 the pl&let is unop- 
‘posed; thus, thvmb&s C+UI still occur despite’ aspirin (33). 
Similarly,, heparin has severa{ Iimitatiotis: Hepafin is &it+- 
mn thrombin inhibit& whose efieti is dependent ui~ the 
&factor antithrombin III, (34,35). Furthermore, heparh ‘is a 
fietero~neous mixture ‘of mulecules with varia& biologic 
i#e#s, which may Xead to variability in its antic.~~@~~t ikcts 
(35,36) and to decreased e3kacy (37-42). Furthermore, jbep 
kin i$.i&ibi@d by prdtehksecreted by activated plat&ts, 
such as platelet factor 4 (35.43-M). Finally, and perhap most 
important, hepakin cannut inhibit ciot-bound t$ombin (47),. 
thereby potentially, limiting its ability ti, “passivqte” an krive 
t@romb&ic lesion,(Fig. 1). 
The search for eEeclive antit.hrombotic agents has foiquskd 
On the cent&! rok ;Of thrombia in arterial thrombok Throm-, 
,hi,in-has three tiajpr t@Ms: 1) If ponverts fibrinogen to fibrin. 
in’ the final cumman, pathway for :clqt formation; 2) it is a 
‘pow&l stimuiui ‘fur .pl$elet aggregation;. 3) it. actiira;tc~{ 
,Fqctor ,x111,’ which lea+ ,to CtoWinkiu~ and stabiI&a&n’ of 
ithe fibrin clot (48); T&im@n molecufe~ are incorporated into’ 
12o~ooaiy thrombi (Fig. I) &d c+n form the nIdus of retk6m; 
basis & the thrombus utidergoesendogenous fibrin&y& (i.e., 
in ui&bk angina) 6r:is,dis$l~d by exogenous~.ad~i;ste:~d., 
_~~.m~!~“k’&nts (i.e., in pccute myocardiral @aictiq& Hep :. 
arin is unable to:khi&t clot-bound thrombia, IargeIy bt~~& 
the heparin bindii &te of thrombin is not ~&bk 10 the 
heparin-arrtitbin Iif complex (47) (Fii: 1). Great ‘inkrest 
‘FigMe 1. Rokpf thronk:i~ the’progr&&on df @+CXXI~L& iir tivte 
coronary hdmmes. Thrombln is ikxporated within a fibrin CM As 
fibrinolysis occurs, &her e&ogenously or aftei thrombolytic therapy, 
thrombin molecuIes are cxposed and can induce rethrombcG (Ai. The 
heparin~tithrombin III complen cannot i ihibit cbt-boulld thrombin 
be&&e the.biriding:site for be* on the thrombjrLmolectde is not 
,accesst%le. In ‘ccntrast, hirudin, can inhibit ~lot~hni! thrombin (B). 
ATIlf = anti+* IS! yJXM4 =, wb”“y~ teminu? NH, = miiho 
termigus. 
,‘. ;, :‘; 
‘h&’ be& focus& on thk direct thro*bin ~inh&itors, ‘n&bly 
hirudin;.$hich add&s many CC the@ limitations:’ ] .: ” ” 
: ” .! : .: 
; ,Hiedin is a .65-&@&Ad pc$pepfide ‘derived km’ the 
leech .~irudo :~ttx@n&s that -acts aCti, poterit and.’ s&&e 
inhibit& of th&mbin:‘(49) (Fig:‘2). l-&din sektikely binds 
thrombin in a I:1 fashion at :IWO sites: 1) The 12-ukio-acid 
carboxy terminus of hipdin b&is to tk subspmte recDzflition 
site, the danpin of tbrombin that reiognizes fihrizogerr @I) or 
the #at&? (?l); and 2) the amino terminus of hiruG L binds to 
th@ &a&tic site of thrombin (SO), thus -r&ing it a dikct, 
specillc inhiiitor of thrombm. Becatise ok The specificity of the 
‘carb~ kr&~us binding to’thn;mbin, himdin does not inhibit 
other enzymes in the ccra&Iation or $b;inolytk pathway, such 
fl% Factors Xa and rX, kallikrein, activated protein C, plasmin 
or tissue-type ph&ninoge~ k~tivsror (t-PA) (49). The bitiding 
,af hipdin to -bin, is not cuvaknt. However, the I%-- 
tin. rate .is extremely shv, making hirudin un essentially 
ir&ersr%@.‘ inhibitor of thmmbin (49,52). The himdin- 
tbromk timpI? circulates in the blood for -4 to 6 h, after 
dtj$cjr it is ckared by the r&icuIoendotheliaI system. Circu!at- 
kg free hi&din is excrete+5 by the hidnejls, and, thus, dose 
adj~xnts must be tide in thi presence of renal dysfunction 
(53,. 
For ckkal use;hirudin~is p@uccd in yeast by rewmbi- 
r&h. lW.2 l &nok@ Recoibinant desulfatohiru~in is idcn-- 
“3 to hdin .except fc::: a ~lqisihg sulfate group. oii the 
tyrr~@e 63 (54). Experimental studies (49,54) have demun- 
.str~tzJ &at &sttIfatohirudin inhibits ail of the major actions of 
tbr@nbin, irwludiq thrombin-induced genera~on of fibrin anJ 
tkombii-indti pIate#es, activbon,. as well as ‘thrombin’s 
autocatdytk re+ctioo. R&&al adknages :of tiirudin over 
hepar@ arc that h&&ii ee;n irihibit dot&our@ tlk@tibin (47) 
,@ig. 1X is not inbibited,by activated platelets (55) kd does not 
rkquire a cofactor &d th& may exert A. more &able antieoag- 
lJ&t respO~‘(~4). .:, ,,‘, ‘. : .: .’ 
j ~&&.&.&($&.&~~ I. : 
The anticoagulant pro@izies ,of hirudin were first demon- 
stmlcd in a’variety of experimental preparations. &vat+ of 
thsx3.xti time, &ated partiaf .thromboplastin -time, -any 
were ~&served (56). The antithr&Mtic 
were seen fn B pig niodd of deep arterial 
.&jay, In which l&r&h was iiwre eEeetive chair hqkn in 
inhibiting both platetet’ deposition and tbrombus form&ou at 
the site &f arterial injury(57,58). En a.caniae mbdel ufqxonriry~ 
~hrontbosis,, wkqn ‘@en with the :tbromboly?id agent’ t-PA, 
hirudin was more eff& than bep&in or aspirin in speedir$ 
thrombolysii an:.l iir prkveniitig reokhtsion~(~9~. In a similar 
model, using streptok$s.z’ ai thei tbromlidyt~- &gent (60); 
hirudin was found to. IncreiiSe the : total” time tif -rep&us@ 
compaied with’heparin and:to decreati Wrcsidti.=l thrombus 
mass at, a laker degree of ;rru@oagulatio&, as judged by the 
activated partiai thrombopl~tin tir&Thus, in severa! models 
of arterial thrombosis, hirudin appeared to be mare etktivc 
than heparin and thus warrant@ furthe;, testing in patients 
with acute koronary sjmdromes. 
Anticoagulant effetik. An initial study of hit-u&l in humti 
volunteers by Yerstmete et aLf61) demonstrated that hirudin 
produced a dose-dependent increase in the activated partial 
thromboplastin time, prothrombin time and thrombin tinie. In 
a subsequent study in patients. with stable coron&y artery 
disease by Zoldhelyi et al. (62), hirudin produced, a dose- 
dependent increase in the actiGated partial thromboplastin 
time, and the half-life of the effect on the activated partial 
thrombopltitin time was between 2 and 3 h, The activa:ed 
partial thromboplastin time ratio to baseline correl+ed we!: 
with the plasma hinidin concentration (i r W%3). The .xii: 
.vated clotting time .also correlated well with hiruairt -level (P =.’ 
0.80). althkgh at the doses tested, the ran& of activated 
clotting time values was sm@er, from 155 to 230 s compared 
with a wider difference #I activated partial thromboplastin 
time, from 75 to @l s, makjng the activated dotting time a,less 
sensitive test in this dose range, The &ape of the activated 
partial thiomboplastin ‘time respunsc io hirudin do& was 
curviliriear: at doses X0.1 mg/kg body weight per h, the in- 
cr&+e in the activated partial thromboplastin time.* pro- 
portional to the’ increaq in dose, whereas :>a. i mg/kgper.h;. 
ik iric&ase in. activated, partial ihrombo@tstin time’ was less 
Steep. The thrombih time *as too sksitive; with even the 
O,K&mgfkg per h dose proionging the thrombin time to >600 s. 
me prothrombia timewas the lea+ sensitive test, although the 
highest dose, 0.3 mglkg per h,.prolonged:the protbromeirr time : 
ici in inteinational n&naked ratio’ of 2.3, hi&er .thtin the 
level usualty occurring with hepar& Thttq the activatehl p&M 
tbromboplastin time appear,+ to be. useful to-gauge tbe,tevel 
of qkoagulatiou ‘in at&lies of: bi+lin, &uug@ the “thera~ ’ 
gieutic ‘range’: .of:activated partial thrumbdplastin timti~ ,foi 
efficacy any safety could be dctcrrrSned only from c!c!ir$zal trial! 
:by correlating the lev& of activated ‘partial thr’omboplastin 
tin$‘with dinic$esd p&s (e.g., bleeding). 1’: ’ : ~ 
..The antiwaguhnt &ectibf hirudin were similzkr in,the, piI& 
trials of hirudiri in the treat&nt .of three &otips ,of patients: 
with ckiary. artej d&se: & adjunctive therapy to tirn: 
bolysis in patien&~&th ‘acute myocaklial infarction (6%651, 
for unstable’ angina and non-Q wave myocarclial infk%ion 
(66) .and during angioplasty (67). In addition EO dose- 
dependent increases in activated partial thromboplastin time, 
hi&din was found to achieve a v~ty consistent Ievel- of antico- 
agulation (Fig. 3). Unlike heparin, with which wide fhtctuations 
in activated partial thrombopIastin time arc common, hin& 
Gintained a ‘stable activated partial thrombdplastin time 
throughout the-‘infusicn period in a far greater @oportion df 
patients than heparin, a Gnding that was consistent across all 
the three patient popultititins. The, ability to achieve a more 
stable actktcd par&d thromboplastin time may .be an impor- 
&mt mechanism of laieL because .it Elvoids periods of kde- 
.ipa!e antimagulatb~, which have been shown to have ahrerse 
dinical cunseguenaes (3%39&58). 
” Acnte nqaxwdid ,lnfar&m. Hirudin has been evaluated 
88 aa adjwrct to,tfirombo@tic therapy in three pilot trials, two 
of which, the ‘Ilh41 5 triaf (Q3) and the Hirucjin for the 
Improvement of Thrqmbolysis (WIT) trial (64), used t-PA, and 
the third, TiMI 6, used streptokinase (65). These three trials 
gave insights into the elk+ of hi&&r on.,the rttajcr limitations 
bf lcqrrent ttiombo!ytic rqiaiens, incompbt~ ‘initial rep&u- : ,; 
sion, rwcclusion of the infarct-related artery artd of major 
clinical events, inchtding its initial safety pro!& (69). 
The TIMI 5 trial was a dose-ranging trial that cumpar&f 
intravenous hirudin with heparin, in conjunction with t-PA ,+d 
aspirin in 246 patients @ese&it$ with acute my&&dial infarc- 
tion within 6 h. EtigiiIe patienti were randomized to receive 
either heparin or hirudin at one of four ascending doses, 
ranging from a 6,JS+q$&g bolus folIowed by a 0.Smg/kg 
per h infusiun to a O.&mgkg. b~lus and a O-2-mgkg per h 
infusion, which was cuntiuued for 5 days. 
To evaluate early, cumplete and susttied rep&fusion, the 
primary end point of the TIME 5, trial was the ach+ment uf 
TlMI grade 3 lhw (18) at both 90 min &xi ig to 36 h with&t 
death or reinfqrction before the 18- ‘to 36-h angiograrn. Sii 
ty3 pcent of hiru~;n - Ireate patients ach@ved this %ptimal” 
degree of reperfusion compared with only 49% of @par& 
treated patients @ = 0.07) (Fig. 4). At 9o:min, there was a 
nons&i&ant trend favo&g: hirudin in TiMI, grade 3 ffow 
(65% vs; 57%~ for I~ep*), ~,+n~gkinfatctre#ated :. artery ‘. 
Fig& 5. Eff&ts.of hirudin and, he&l-in on ciin- 
ical ehd,pdiats in patients with ?Cuk mioi?diai 
infarction (MI) (63) and unstable angina (66) and 
after cwwky~ngbplasry(FTCA) (67). CA3G = 
cuninary a+ry bypass grafting; CHF = &ngestbe 
heart failure. 
Y*: 50 116 N= 
60 rnirl was achieved in, 50%, 575 and 41% of the three. 
ascending dose groups, respectively. At 36 to 4X h, TIM1 grade 
3,tlnw was present in 72.2%, 75.6% and 92.0% of patic+r in 
the three da& groups. Reijcclusiori occurred in 6.7x. 5.~% 
and : 1.2% and reinfarction occurred in 0%,,4.8% and .1.2% of 
the three groups. Major spontaneous hemorrhage occurred in 
0% 2.4% and 2.4%, although an inciease in instrumented site 
‘bleeding was noted at the highest dose. j 
The TiMi 6 ‘trial was a trial of hjrudin in corijunctiati with 
streptokinabe and a&pirin (65). T&ee doses bf hirudin (boluses 
followed by infusion rates of 0.05, 0.1 and 0.2 mg/kg per h) 
were tested with a heparin compa&n group in a trial.of 1’93 
patients. AIthough the pilot. trial was not sized to ‘detect 
Uerences in effic;icy, favorable trends were observed. The 
incidence of death, myocardial infarction, severe congc&ve 
h&art failure or car&q&c shock occurred in 21.6%, 9.7% and 
--l&4% of hi++eatcd piients’iq the three ascendink do& 
groups, respectively, &ompxed with ‘lSr;6%. of hepari&tr&ated 
patients; Majbr hemotiii&ie;’ either. spontanebtis or. at -&A. 
instrumented site, ,occurred in hospital in 5.7% of hirudin- 
treated patient; and 5.6% of heparin-treated patients (p = NS) 
(65). : : ; 
Phpse I@ &jls: safety ohseflations; As k4,result of the 
favorable. e,Be& of hipud@ as compared with those of hepgiin 
observed in these phase II: trials, hirudin is now ,being tested iri 
seved large phase Iii &dglg. Mihough hiru+ appeqred,to be 
@ite.:&fe ,iri the re~ativelyqnail bhase II‘trials; a bolus dos$ of 
0.6 mg/kg fdlIo+ed.by +I i&&tin of 0.2 m&kg per h, whei’. 
g@n together tith a thrombolytic agent and asp++ .in the 
early phases of the three IaGe phase II1 trials, was associatid 
x&h &n ext.--e& of bleeding (as was a higher dose’.qf heparin). In 
~hr,l9A, @I which patients receiyed-aspirin pd either’t-FAor 
slrcptokinase, the .intiidFnce of ++zranial hemoirhage was 
‘. 1.8% in, hint+-treated patitints and, 1.9% in hep&in-t&&l 
,patients (p =,, NS) (72); Major sp~ltartt!~us hein3mhage was 
‘$sa higher than expected. 8.7% .fcir hirudin and 4.4% for 
b&t3 and ,a U15-~g per h Won; TIMI grade 3 flaw a: hepark (p = &I!5) [72). fn GL”;ka”r) IIA, in p&e& tr&ted 
patency ($IMI gradi 2 or 3 flow) &s sirnil& in the two groups, 
82% and’ 79%, respectively- No differ&es in angiographic 
finding were found among the hf flozs. Ah 18 to 36 h af 
antithroni5uiic .$herapi, infarct-related ti&y patency was sig- 
‘n&a&y higher in h@din-treated patierits (98% vs. 89% of 
heparin-treated, patients, p = 0.01). A component of :hia 
improved patency w& a d~cr’eqse in inlarct-related artery 
r&e@ion, which o&r&d in 6.7% of heparin-treated pal 
‘:tients cornpan& with onty 1.6% of hitidin-treated patients 
cp = 0.07). j 
For tilti& ind points, similar favorable effects of hirudin 
~tiere noted. The comp&te end p&t of death, reinfarction nc 
new severe congestive heart ,failtire M cardiogenic shock 
md.in 19.0% of heparin-treated ‘patients compared with 
‘9.3% of @dig--ted patients (p = 0.03) (Fig 5). Death or 
r&fxy&on occurred in 16.7%. of heparirt-treated patients 
eonqared with 6.8% of hiruSin-treated patiqtts’(p’ = OK!). 
mti primary sgety edd point cff the t&&tias~major heax- 
o?hage q defined hy standard TIM1 cr&ria (70): Major 
hemorrhage, :eithq spotitmus or at a~ instrumented site, 
-oc&srqd in 23% of hepa&-Fated patients compared with 
17% of hlrudii-treated patients.. Across ihe’&r ,dose& the 
rates of major hemorrhage were,’ 135%,. S.S%, 13.8% and 
29.4%. Ftrxmse activated partial thromboplastin, $mc values 
fose in a dose-depetident fashion; it appeared that the asti- 
wkd p&th~~m~l~tit~ &ne tight be a uiefui me&uie in 
predkting lhzdingm F&t& analyses demonstr$,ed that an’. 
advati gmlid thrombdpla@in time ,51-00 s~,ti~ass&iattid 
with an increased incidence of major hemqtihage (7i); Roy- 
ever, spontaneous fnoni&rumented site) hemorrhage was 
ir&req~~ 5% for hepariti Bad c-r# 1% for h&din. 
T&e I-UT $al aiso sttidiid several d&es of hiruc&n with 
lhmt-loaded ,c-PA aQd &q&in but did not have -zi hep&n 
crmphn .gruup (644); Une &&red. forty-three @tier& 
reded one of thr& ttsmdhg dwes of himdim, ranghig frdm 
‘” $l+y@g beha and Q.O?-q&g per h’infttsion to B 0.4-rr@kg 
J*CCVol.25,No.7(Sup~iement) 
.:: 
hie 1m:3*F : .: 
.. ., ,.~ :, ,.’ 
:, ‘. 
‘. ,, 1 .j: . .: 
;.. .‘. “,: ; 
,with, ~hr$nbol$iti the&y, irkcranial hemorrhage occ&ed 
in 2.2%. of, birudi&t.Eated &ients -and 1.5% c$ hepkin-~ 
tfeakd patients (p .= NS) (73). Tlpse obscrvatks, together 
w@ sin&r find& iii the ,HlT III trial (74),, Ied to a reduction 
of the d&e of hkudin in both TIMI 9 and GUSTO, II, to-a 
bohi of 0.i mg/kg followed by an infusion of 0.1 mglkg l+ h. 
Further, b@use the hctivated partial thromb~$kstia time .’ 
*pears to correlate with hemor@&gic qveuts (71), the l&&n 
and : heparin infusions are adjusted to j maintrjn an- ktivated 
partial thromboplastin time of 55-s s (72,731. 
The findings of TIMI 9A, GUST0 ILA and Wf ill 
demonstrate, that in patients treated with thrombolytic therapy 
and aspirin, higher.lqels qf knti&~lation with either liirudin 
& heptin ,appear to be aswclated with excess bleeding and 
intracranial ‘hemorrhage. Thus, it is especially important to 
maintain the Ievel of anticoagulation within the therapeutic 
w&low between inadequate titicoagulatioa (37,381 and ex- 
cessive anticoagulation .(as observed in TIMI 9A, GUSTO llA, 
HIT III and the Primary Aqioplasty in Myocardial Infarction 
&al [PAMI]), which reported a 2.0% iucidencc of i,-;:racranial 
hemorrhage following t;FA znd lQ,OOO-tinit bolur of heparin 
(75). However, with lower doses, of h+lin it should be, 
possible to determine whether, at a similar level of &i&g- 
ulation, the benefit;-of hirudin in inhibiting clot-bound’throm- 
bin translate into I,nprov+ clinical tiutcome ktzowing acute 
myocardial infarction. 
UnstabIk @a firudin was kmpared withhepkin in 
patients with unstable angina. and non-Q ‘wave myocardial 
infarction in an angiographic trial conducted by Topol et al, 
(66). Patients presenting with ischernic Paul and electrocardio- 
graphic dxmgks at rest who, had angiographic evidence of 
coronary thrombus were eligible for the study. Gne hundred 
sixty-six patients were randomized to receive one of t-w? doses 
of heparin (either a. target activated partial thromb+~ri5 
time of 6S to 90 s or a ta;get of 90 to 110 s) or hirudin at one 
of fair d* (ranging from ‘a @X5-mg@g bqlus followed by a 
fl.~~-tngkg pkr h c&kttit h$nsion:up to a O.~mg/kg bolus and 
a 0:3-mg/kg per h i&&n).-Patknts rkc&ed a S-day infusion 
of open-label study,‘drug, and the primary end point was 
improvement in lesion severity at the follow-up angiogram. 
The &rage cro&r&tipnal area:‘bf the coronary lesion 
improved more in hi&din-treated patients, 0.32 rrun2< thrm is: 
‘. hep&t-treated ~~t&ts, 0.08 r&* (p = OB3). ,0ther ‘indexes 
of l&on improvkmeqt followed ‘the same pattern: minimal 
humeri diameter improved by O.lS’rr@with hkudin compared 
with &tly 0.03 ‘mm2 v&h hep& (p + O.I)3), and the &nges 
in. it&ml c&s-&tional ‘&a. were 0.29 and 0.10 m@?, 
respectively ti 7. O.fB). h shbwn in Ftgrue 4, aslightly higher. 
‘percent of. patknts dcmkstrated ti. impr~ement~ in TWlI 
fiti&ade Iover the’Sjay per&l, -, 
Although this angiogra@k trial .y& ‘not +slgaed to &l- 
uate clinical end p&s, no d&&s occurred ‘m either treatgent 
ami, and a;low& incidunce o; poSciandorn,iza.tion’~~oc.~~i~ 
infarctitin occutred in hirudm-treated pdknts (2.6%~~. &II% 
fix hepar&Fated patie@.& p = $Ul). The wnposite end 
po&t of deatfa, myocar@ial infarck or recurrent.. angina 
oocvrkd in 24.0% of hcpa&tre&d patients&ml&d &ith 
14.6% ‘of l$rudin-treated patleo& (Fig: 5). These d&a .sug- 
g;sted: that. the rkolutioh of qkonary thrombus, as j-ud&l by 
Varioy &asures of lesion &verity, was asso&t+ith.clin@l 
benefit&n patients with u’@ie &@a and ‘no+Q w&e 
~myocard~al,infa&ou. : ’ i ; 
Arjgiopissty. A,pilot rrial of b-u&n during &ronary aq@- 
plasty ,has also been~‘conducte:l to evaluate wbitber hirudin 
might reduce thrombotic: coirfilications following. angioplaky 
(67), One bundfed thirteen g!tients with stable coronary artery 
disease undergoing electivf/balloon angioplasty were random- 
ized in a 25 ratio to, rec:he hirudin or keptin,: Hirudin .was 
administered just befr,!z the procedure ‘as a 20-mg- ?HJIUS 
-ye followed by a O.l&$.j kg per h infusian for 24 h, and hqarin 
was given as a 10iXl-U tilus followed by a l?-U/kg per b 
infusion;with bottt infusions adjusted to maintain the activa:td 
partial thrbmboplastin tune between 85 and 120 s. 
At the 24-l fcJlow-up angiogram, full perfusion (TIM1 
grade 3 flow) (1s) was~observed in. 100% of hirudin-treatd 
patients and 91% of heparin-treated patknts (Fig. 4). During 
the 24-h period after angioplasty, with continuous ST segment 
Hotter mo@orin& signikant iscbemia was observed in 4% of 
hit-&in-treated patients compared with .14% of heparin- 
treated patients. 
There were no deaths in either group, but fewer patients 
had a m-dial infzsrction ‘following the procedure: none for 
hirwjin cbmpa@d with .5;1% for heparin ,(p. = 0.05). ,For the 
composite end point of death, myocardial infarction or need 
for emergency bypass surgery, a lower incidence was observed 
in hirudm-treated patients (1.4% vs. 10.3% of heparia-treated 
patients, p = 0.03) (Fig. 5). 
Results of the double-blind HELVEWA trial have re- 
cently been, reported (76). Gne thousand one hundred forty- 
one patients with new-onset, worsening or rest angina under- 
going ~,bsllkm a@iopl&ty ‘yre raudonked to either. 1) 
intravenous hepark bolus (.lO,WlO U,) tid .24-h kf&ion (15 
U/ki pei h); 2) intiaventi hi&in boluz (40 mg) and 24-h 
infushr (Ir.2 m& pet h); or 3) intravenous hifudin b&s 
(40 mg) ;uld ?4-b i&sick (0.2 r&/kg per b) foHw+ 9 3 days 
of sujxk+~~Us. @wli~~ (SO mg twkb da@). The tideace,of 
angiogra@ic restemk’at 6months was sot different “Ong 
the three groups. How&r, thti in-hpspi~ai iwiden=. (!o % hj! 
of.‘d&&, my-d8 h@ytion 0; repeat intervention WBS 
sigtklintiy reduced itithe hifudin af& +I% foi be+n 
~$ped with ‘7,!4% for intra&~~~ tidin and 5.5?6 for 
int~;qmus Andy &cut&&us hirudin (&@ee-way y ‘=, 0+@3) 
(76). Aithougb a follow-,up trial &ng”cii&l eti-nts as the 
t&q end poir~t will likely be n&d, tiesi: results Suppoit 
the’ micept ,that mm- pbtent aj&qula~Eon *t.b hirudb 
rec!u& recur&i .&hem@ events aft+ an$oplastjr. 8f *pqr- 
: tan&, major bt&dihg complications in hirudin-treat&l patiekts 
were sin&r to thy for hepa;rin: 6.2% for hefkrin, &S% for 
intravenous hirudin aad 7.6% for, mtraven!uts plus subcutan~- 
:&+itwiin (p’ iyS) (76). .; y: 
Thus, ttik initial .expqience ‘4th h@udin~‘a~oss the spccl 
mm of acute coronary syndrqmes has, showr. promising re-i 
s&s. The antico@knt profile of. hirudin demorktrates a’ 
‘pdictable, dosedepetident &~cre& in a@&ied partia! ; 
thrombopkstin tin& with a more stable !eveI. of anticoag$a:, 
tion GompaFed with he@rin. In a&e, myqszkjial i,nfarction,: 
hirudin, in ckjunctiojl with thro@olytic, therapy, ,&as associ-, 
ated with a higher incidence of early and sustained riMI gra&i 
3 tiw. decreased infarct-related artery reocclusion and a lower 
itidencc of in-hospital death, reinfarctiqn or severe conges- 
tive heart failure thm heparin. In:unst.able angina and non-42 
wave myocardial infa&on, hirudin appeared to imprake the 
resolutiori of coronary thrombus and t’educe the incidence of 
recurrent ischemic events. Similar red&ions in recurrent 
itihemic events,were observed in the init@ trials using hirudin 
during baIoon angioplasty. Although excess bleeding was 
observed after thrombolytic therapy at the i).Zmg/kg per A 
‘infusion d&e, a 0. l-mgkg per h illfusion is r!ow being tested. 
: Imp&ntl& no Excel bleedifig was dbserv&l at the 02n&kg 
per h MuGon do& during angiopkty (withou! thrombolytic 
therapy). Thus, ‘it, is hoped that, the %vorable Iesults in tk 
initial phase II trials can be confirmed in the :Fngoing TIMI 9 
&nd GUSTO Ii triakkd that hirudin kill provide a further 
adv&e in the tr@tment pf acute myocardial infarction and 
acute coronary syndromes.’ 
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